• By ICR Secretariat
• Posted Monday, June 6, 2022

Merck study results signal blood cancer potential for new type of immunotherapy

https://www.biopharmadive.com/news/asco-merck-favezelimab-lag3-hodgkin-trial/624457/

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat Merck to a notable milestone by winning U.S. approval of a first-of-its-kind cancer immunotherapy.